| Citation: |
WU Yarong, ZHANG Yongqiang, ZHENG Ying, WANG Caihong. Advances in Mechanisms of Portal Vein Thrombosis in Liver Cirrhosis[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 439-447. DOI: 10.12290/xhyxzz.2024-0924
|
Portal vein thrombosis (PVT) is one of the most common complications of liver cirrhosis. The formation of PVT can increase the mortality rate of cirrhotic patients and adversely affect the successful implementation and prognosis of liver transplantation. A hypercoagulable state is a unique mechanism underlying PVT formation in cirrhotic patients. In recent years, the pathogenesis of PVT has gradually been elucidated, with specific mechanisms including the following aspects: systemic and local inflammatory responses lead to vascular endothelial cell dysfunction, thereby promoting the activation of the coagulation system; abnormal activation of the monocyte-macrophage system exacerbates local inflammation, enhancing platelet adhesion and aggregation, and facilitating thrombus formation; an imbalance between the coagulation and fibrinolytic systems results in a sustained hypercoagulable state; and intestinal microbiota dysbiosis induces inflammation and metabolic disturbances, thereby increasing the risk of PVT. This article summarizes the latest research progress on these key mechanisms and their interactions, providing new insights into the molecular and cellular mechanisms of PVT. It also offers directions for the early diagnosis of PVT and the exploration of novel intervention strategies in the future.
| [1] |
Pan J H, Wang L, Gao F B, et al. Epidemiology of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis[J]. Eur J Intern Med, 2022, 104: 21-32. DOI: 10.1016/j.ejim.2022.05.032
|
| [2] |
Elkrief L, Hernandez-Gea V, Senzolo M, et al. Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies[J]. Lancet Gastroenterol Hepatol, 2024, 9(9): 859-883. DOI: 10.1016/S2468-1253(24)00155-9
|
| [3] |
Senzolo M, Garcia-Tsao G, García-Pagán J C. Current knowledge and management of portal vein thrombosis in cirrhosis[J]. J Hepatol, 2021, 75(2): 442-453. DOI: 10.1016/j.jhep.2021.04.029
|
| [4] |
Iwakiri Y, Trebicka J. Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy[J]. JHEP Rep, 2021, 3(4): 100316. DOI: 10.1016/j.jhepr.2021.100316
|
| [5] |
Gong H, Zhong H, Xu H M, et al. Insight into increased risk of portal vein thrombosis in nonalcoholic fatty liver disease[J]. Eur J Intern Med, 2023, 114: 23-34. DOI: 10.1016/j.ejim.2023.06.011
|
| [6] |
Xing Y Y, Tian Z B, Jiang Y P, et al. A practical nomogram based on systemic inflammatory markers for predicting portal vein thrombosis in patients with liver cirrhosis[J]. Ann Med, 2022, 54(1): 302-309. DOI: 10.1080/07853890.2022.2028893
|
| [7] |
Violi F, Pignatelli P, Castellani V, et al. Gut dysbiosis, endotoxemia and clotting activation: a dangerous trio for portal vein thrombosis in cirrhosis[J]. Blood Rev, 2023, 57: 100998. DOI: 10.1016/j.blre.2022.100998
|
| [8] |
Jiang S Y, Ai Y J, Ni L Y, et al. Platelet-derived TGF-β1 is related to portal vein thrombosis in cirrhosis by promoting hypercoagulability and endothelial dysfunction[J]. Front Cardiovasc Med, 2022, 9: 938397. DOI: 10.3389/fcvm.2022.938397
|
| [9] |
Huang X Q, Fan X W, Zhang R, et al. Systemic inflammation and portal vein thrombosis in cirrhotic patients with gastroesophageal varices[J]. Eur J Gastroenterol Hepatol, 2020, 32(3): 401-405. DOI: 10.1097/MEG.0000000000001526
|
| [10] |
Georgescu D, Ancusa O E, Azoulay D, et al. Portal vein thrombosis in patients with liver cirrhosis: what went wrong?[J]. Int J Gen Med, 2023, 16: 3889-3906. DOI: 10.2147/IJGM.S413438
|
| [11] |
Xu X T, Jin J L, Liu Y W, et al. Analysis of related factors of portal vein thrombosis in liver cirrhosis[J]. BMC Gastroenterol, 2023, 23(1): 26. DOI: 10.1186/s12876-022-02632-z
|
| [12] |
Driever E G, Magaz M, Adelmeijer J, et al. The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study[J]. J Thromb Haemost, 2022, 20(9): 2075-2082. DOI: 10.1111/jth.15797
|
| [13] |
Li W, Cao T, Luo C Y, et al. Crosstalk between ER stress, NLRP3 inflammasome, and inflammation[J]. Appl Microbiol Biotechnol, 2020, 104(14): 6129-6140. DOI: 10.1007/s00253-020-10614-y
|
| [14] |
Takata H, Hirakata A, Ueda J, et al. Prediction of portal vein thrombosis after hepatectomy for hepatocellular carcinoma[J]. Langenbecks Arch Surg, 2021, 406(3): 781-789. DOI: 10.1007/s00423-021-02125-9
|
| [15] |
Molinar-Inglis O, Wozniak J M, Grimsey N J, et al. Phosphoproteomic analysis of thrombin-and p38 MAPK-regulated signaling networks in endothelial cells[J]. J Biol Chem, 2022, 298(4): 101801. DOI: 10.1016/j.jbc.2022.101801
|
| [16] |
裴寅煊. 穿心莲内酯预防大鼠急性门静脉血栓形成的效果和机制[D]. 承德: 承德医学院, 2024.
Pei Y X. Effectiveness and mechanism of andrographolide in preventing acute portal vein thrombosis in rats[D]. Chengde: Chengde Medical University, 2024.
|
| [17] |
Che Y, Chien Y, Zhu Y L, et al. GSDMD-dependent neutrophil extracellular traps mediate portal vein thrombosis and associated fibrosis in cirrhosis[J]. Int J Mol Sci, 2024, 25(16): 9099. DOI: 10.3390/ijms25169099
|
| [18] |
Zhou X, Hu Y Q, Sun H, et al. Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in hepatocellular carcinoma[J]. Eur J Nucl Med Mol Imaging, 2023, 50(10): 3107-3115. DOI: 10.1007/s00259-023-06251-y
|
| [19] |
Leberzammer J, Von Hundelshausen P. Chemokines, molecular drivers of thromboinflammation and immunothrombosis[J]. Front Immunol, 2023, 14: 1276353. DOI: 10.3389/fimmu.2023.1276353
|
| [20] |
Li W Y, Chang N, Li L Y. Heterogeneity and function of Kupffer cells in liver injury[J]. Front Immunol, 2022, 13: 940867. DOI: 10.3389/fimmu.2022.940867
|
| [21] |
Ørntoft N W, Blé M, Baiges A, et al. Divergences in macrophage activation markers soluble CD163 and mannose receptor in patients with non-cirrhotic and cirrhotic portal hypertension[J]. Front Physiol, 2021, 12: 649668. DOI: 10.3389/fphys.2021.649668
|
| [22] |
Gao F B, Wang L, Pan J H, et al. Efficacy and safety of thrombolytic therapy for portal venous system thrombosis: a systematic review and meta-analysis[J]. J Intern Med, 2023, 293(2): 212-227. DOI: 10.1111/joim.13575
|
| [23] |
Sinegre T, Abergel A, Lecompte T, et al. Prothrombin conversion and thrombin decay in patients with cirrhosis-role of prothrombin and antithrombin deficiencies[J]. J Thromb Haemost, 2024, 22(5): 1347-1357. DOI: 10.1016/j.jtha.2024.01.016
|
| [24] |
Lebreton A, Sinegre T, Lecompte T, et al. Thrombin generation and cirrhosis: state of the art and perspectives[J]. Semin Thromb Hemost, 2020, 46(6): 693-703. DOI: 10.1055/s-0040-1715102
|
| [25] |
Pradhan-Sundd T, Gudapati S, Kaminski T W, et al. Exploring the complex role of coagulation factor VⅢ in chronic liver disease[J]. Cell Mol Gastroenterol Hepatol, 2021, 12(3): 1061-1072. DOI: 10.1016/j.jcmgh.2021.02.014
|
| [26] |
Davis J P E, Caldwell S H. Healing gone wrong: convergence of hemostatic pathways and liver fibrosis?[J]. Clin Sci (Lond), 2020, 134(16): 2189-2201. DOI: 10.1042/CS20191102
|
| [27] |
Wu Z N, Xiao Y, Qi Z Q, et al. Effect of factor Ⅷ and FⅧ/PC ratio on portal vein thrombosis in liver cirrhosis: a systematic review and Meta-analysis[J]. BMC Gastroenterol, 2024, 24(1): 320. DOI: 10.1186/s12876-024-03399-1
|
| [28] |
Naguib M, Abdel-Razek W, Estaphan S, et al. Impact of prothrombin and factor V Leiden mutations on the progression of fibrosis in patients with chronic hepatitis C[J]. PLoS One, 2022, 17(11): e0276592. DOI: 10.1371/journal.pone.0276592
|
| [29] |
Van Cott E M, Khor B, Zehnder J L. Factor V leiden[J]. Am J Hematol, 2016, 91(1): 46-69. DOI: 10.1002/ajh.24222
|
| [30] |
Fortea J I, Carrera I G, Puente Á, et al. Portal thrombosis in cirrhosis: role of thrombophilic disorders[J]. J Clin Med, 2020, 9(9): 2822. DOI: 10.3390/jcm9092822
|
| [31] |
Kang H, Kim S, Park S, et al. Small leucine zipper protein negatively regulates liver fibrosis by suppressing the expression of plasminogen activator inhibitor-1[J]. Exp Cell Res, 2024, 442(2): 114258. DOI: 10.1016/j.yexcr.2024.114258
|
| [32] |
Derraz I. The end of tissue-type plasminogen activator's reign?[J]. Stroke, 2022, 53(8): 2683-2694. DOI: 10.1161/STROKEAHA.122.039287
|
| [33] |
Sandoval-Rodríguez A, Meza-Ríos A, Mena-Enríquez M, et al. Gene therapy with urokinase-type plasminogen activator regenerates liver tissue[J]. Gac Med Mex, 2021, 157(5): 508-515.
|
| [34] |
Noguchi R, Kaji K, Namisaki T, et al. Novel oral plasminogen activator inhibitor-1 inhibitor TM5275 attenuates hepatic fibrosis under metabolic syndrome via suppression of activated hepatic stellate cells in rats[J]. Mol Med Rep, 2020, 22(4): 2948-2956.
|
| [35] |
Zermatten M G, Fraga M, Moradpour D, et al. Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis[J]. Hepatology, 2020, 71(6): 2135-2148. DOI: 10.1002/hep.31201
|
| [36] |
Thaler J, Lisman T, Quehenberger P, et al. Intraperitoneal activation of coagulation and fibrinolysis in patients with cirrhosis and ascites[J]. Thromb Haemost, 2022, 122(3): 353-362. DOI: 10.1055/a-1515-9529
|
| [37] |
穆恒, 李恒. 清胰活血通瘀方预防重症急性胰腺炎并发门静脉系统血栓的疗效及对血管内皮功能、凝血-纤溶系统失衡的影响[J]. 四川中医, 2021, 39(2): 109-112.
Mu H, Li H. The therapeutic effect of Qingyi Huoxue Tongyu Formula in preventing portal vein thrombosis in severe acute pancreatitis and its impact on endothelial function and coagulation fibrinolysis system imbalance[J]. J Sichuan Tradit Chin Med, 2021, 39(2): 109-112.
|
| [38] |
刘坤禹, 季慧范, He S, 等. 内皮细胞POFUT1通过抑制纤维蛋白原合成控制损伤诱导的肝纤维化[J]. 临床肝胆病杂志, 2024, 40(8): 1537.
Liu K Y, Ji H F, He S, et al. POFUT1 in endothelial cells controls injury induced liver fibrosis by inhibiting fibrinogen synthesis[J]. J Clin Hepatol, 2024, 40(8): 1537.
|
| [39] |
Gan C, Yaqoob U, Lu J W, et al. Liver sinusoidal endothelial cells contribute to portal hypertension through collagen type Ⅳ-driven sinusoidal remodeling[J]. JCI Insight, 2024, 9(11): e174775. DOI: 10.1172/jci.insight.174775
|
| [40] |
Özkan A, Stolley D L, Cressman E N K, et al. Vascularized hepatocellular carcinoma on a chip to control chemoresi-stance through cirrhosis, inflammation and metabolic activity[J]. Small Struct, 2023, 4(9): 2200403. DOI: 10.1002/sstr.202200403
|
| [41] |
Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(3): 151-166. DOI: 10.1038/s41575-020-00372-7
|
| [42] |
Resch U, Hackl H, Pereyra D, et al. SILAC-based characterization of plasma-derived extracellular vesicles in patients undergoing partial hepatectomy[J]. Int J Mol Sci, 2024, 25(19): 10685. DOI: 10.3390/ijms251910685
|
| [43] |
Zifkos K, Dubois C, Schäfer K. Extracellular vesicles and thrombosis: update on the clinical and experimental evidence[J]. Int J Mol Sci, 2021, 22(17): 9317. DOI: 10.3390/ijms22179317
|
| [44] |
Maucher D, Schmidt B, Schumann J. Loss of endothelial barrier function in the inflammatory setting: indication for a cytokine-mediated post-transcriptional mechanism by virtue of upregulation of miRNAs miR-29a-3p, miR-29b-3p, and miR-155-5p[J]. Cells, 2021, 10(11): 2843. DOI: 10.3390/cells10112843
|
| [45] |
Nie G L, Zhang H L, Luo W, et al. Enhancement of endothelial function and attenuation of portal vein injury using mesenchymal stem cells carrying miRNA-25-3p[J]. Sci Rep, 2024, 14(1): 15113. DOI: 10.1038/s41598-024-64263-6
|
| [46] |
Zhao M Y, Wang L Q, Wang M Z, et al. Targeting fibrosis, mechanisms and cilinical trials[J]. Signal Transduct Target Ther, 2022, 7(1): 206. DOI: 10.1038/s41392-022-01070-3
|
| [47] |
Purdy M, Obi A, Myers D, et al. P-and E-selectin in venous thrombosis and non-venous pathologies[J]. J Thromb Haemost, 2022, 20(5): 1056-1066. DOI: 10.1111/jth.15689
|
| [48] |
Brusilovskaya K, Hofer B S, Simbrunner B, et al. Platelet function decreases with increasing severity of liver cirrhosis and portal hypertension-a prospective study[J]. Thromb Haemost, 2023, 123(12): 1140-1150. DOI: 10.1055/s-0043-1771187
|
| [49] |
Wong D J, Park D D, Park S S, et al. A PSGL-1 glycomimetic reduces thrombus burden without affecting hemostasis[J]. Blood, 2021, 138(13): 1182-1193. DOI: 10.1182/blood.2020009428
|
| [50] |
Tilg H, Adolph T E, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications[J]. Cell Metab, 2022, 34(11): 1700-1718. DOI: 10.1016/j.cmet.2022.09.017
|
| [51] |
Chopyk D M, Grakoui A. Contribution of the intestinal microbiome and gut barrier to hepatic disorders[J]. Gastroenterology, 2020, 159(3): 849-863. DOI: 10.1053/j.gastro.2020.04.077
|
| [52] |
Zhang Y S, Liang X J, Bao X F, et al. Toll-like receptor 4 (TLR4) inhibitors: current research and prospective[J]. Eur J Med Chem, 2022, 235: 114291. DOI: 10.1016/j.ejmech.2022.114291
|
| [53] |
Luo M, Xu Y H, Li J K, et al. Vitamin D protects intestines from liver cirrhosis-induced inflammation and oxidative stress by inhibiting the TLR4/MyD88/NF-κB signaling pathway[J]. Open Med (Wars), 2023, 18(1): 20230714. DOI: 10.1515/med-2023-0714
|
| [54] |
Xia L, Wang X T, Yao W D, et al. Lipopolysaccharide increases exosomes secretion from endothelial progenitor cells by toll-like receptor 4 dependent mechanism[J]. Biol Cell, 2022, 114(5): 127-137. DOI: 10.1111/boc.202100086
|
| [55] |
Keshavarz Azizi Raftar S, Ashrafian F, Yadegar A, et al. The protective effects of live and pasteurized Akkermansia muciniphila and its extracellular vesicles against HFD/CCl4-Induced liver injury[J]. Microbiol Spectr, 2021, 9(2): e0048421. DOI: 10.1128/Spectrum.00484-21
|
| [56] |
李惠, 王学红, 马臻棋, 等. 非酒精性脂肪性肝病患者粪便短链脂肪酸含量测定的临床意义[J]. 临床肝胆病杂志, 2022, 38(6): 1299-1306. DOI: 10.3969/j.issn.1001-5256.2022.06.016
Li H, Wang X H, Ma Z Q, et al. Clinical significance of the determination of fecal short-chain fatty acids in patients with nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38(6): 1299-1306. DOI: 10.3969/j.issn.1001-5256.2022.06.016
|
| [57] |
Li H Z, Shi J L, Zhao L, et al. Lactobacillus plantarum KLDS1.0344 and Lactobacillus acidophilus KLDS1.0901 mixture prevents chronic alcoholic liver injury in mice by protecting the intestinal barrier and regulating gut microbiota and liver-related pathways[J]. J Agric Food Chem, 2021, 69(1): 183-197. DOI: 10.1021/acs.jafc.0c06346
|
| [58] |
Fu K, Ma C, Wang C, et al. Forsythiaside a alleviated carbon tetrachloride-induced liver fibrosis by modulating gut microbiota composition to increase short-chain fatty acids and restoring bile acids metabolism disorder[J]. Biomed Pharmacother, 2022, 151: 113185. DOI: 10.1016/j.biopha.2022.113185
|
| [59] |
Zhang D, Jian Y P, Zhang Y N, et al. Short-chain fatty acids in diseases[J]. Cell Commun Signal, 2023, 21(1): 212. DOI: 10.1186/s12964-023-01219-9
|
| [60] |
Moon A N, Briand F, Breyner N, et al. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist[J]. Biomed Pharmacother, 2024, 173: 116331. DOI: 10.1016/j.biopha.2024.116331
|
| [61] |
Reusswig F, Reich M, Wienands L, et al. The bile acid receptor TGR5 inhibits platelet activation and thrombus formation[J]. Platelets, 2024, 35(1): 2322733. DOI: 10.1080/09537104.2024.2322733
|
| [62] |
Huang L, Yu Q S, Peng H, et al. Alterations of gut microbiome and effects of probiotic therapy in patients with liver cirrhosis: a systematic review and meta-analysis[J]. Medicine (Baltimore), 2022, 101(51): e32335. DOI: 10.1097/MD.0000000000032335
|
| [63] |
Song M R, Liu Y, Huang X Y, et al. A broad-spectrum antibiotic adjuvant reverses multidrug-resistant Gram-negative pathogens[J]. Nat Microbiol, 2020, 5(8): 1040-1050. DOI: 10.1038/s41564-020-0723-z
|
| [64] |
Huang X Y, Zhang Y H, Yi S Y, et al. Potential contribution of the gut microbiota to the development of portal vein thrombosis in liver cirrhosis[J]. Front Microbiol, 2023, 14: 1217338. DOI: 10.3389/fmicb.2023.1217338
|
| [1] | YAN Xinchun, HUO Li. Evaluation of Von Hippel-Lindau Syndrome Through Novel Small Molecular Tracer 68Ga-NY104 PET/CT Imaging[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 911-915. DOI: 10.12290/xhyxzz.2024-0216 |
| [2] | LIU Wanrong, TANG Hui, ZHOU Na, QIU Wei, LI Xiaoyuan, WANG Xiang, BAI Chunmei, ZHOU Jianfeng, ZHAO Lin. Incidence of COVID-19 in Patients with Tumor During the Omicron Pandemic[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1238-1245. DOI: 10.12290/xhyxzz.2023-0281 |
| [3] | ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227 |
| [4] | ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. DOI: 10.12290/xhyxzz.2021-0805 |
| [5] | XIAO Nan, LI Zhanfeng, YAO Jianxin, PAN Zhiyao, YAO Zhifeng. Long Non-coding RNA and Cancer Stem Cells[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 373-379. DOI: 10.12290/xhyxzz.20190231 |
| [6] | Teng ZHU, Hong-zhong JIN. mRNA Expression of Methylase and Methyl-CpG Binding Protein in Peripheral Blood Mononuclear Cells from Patients with Generalized Pustular Psoriasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(4): 358-363. DOI: 10.3969/j.issn.1674-9081.2019.04.009 |
| [7] | Jia-qi ZHANG, Lei LIU, Gui-ge WANG, Wen-liang BAI, Shan-qing LI. Clinical Pathological Features and Prognosis of Non-small Cell Lung Cancer with Skip N2 Lymph Node Metastasis[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 272-277. DOI: 10.3969/j.issn.1674-9081.2019.03.015 |
| [8] | Si-yi CAI, Jian-xiong SHEN, Xi-sheng WENG, Bao-zhong ZHANG, Bo YANG, Bin FENG, Gui-xing QIU. Effect of Comprehensive and Whole Process Blood Management on Allogeneic Transfusion in Orthopedic Surgical Patients[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(4): 286-290. DOI: 10.3969/j.issn.1674-9081.2015.04.011 |
| [9] | Ming-yang LIU, Jie CHEN, Jian GUAN. Local Injections of Cholesterol-conjugated let-7a Mimics Inhibit Tumor Growth and Metastasis of Hepatocellular Carcinoma in a Subcutaneous Xenograft Nude Mouse Model by Targeting K-Ras, H-Ras, and N-Ras[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(2): 133-139. DOI: 10.3969/j.issn.1674-9081.2015.02.012 |
| [10] | Jun LI, Lin-na WANG, He-yi ZHENG. Levels of Interleukin-2 in Peripheral Blood of Patients with Secondary Syphilis[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 395-397. DOI: 10.3969/j.issn.1674-9081.2012.04.007 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: